BAD and breast carcinoma: Additionally, this treatment inhibited the phosphorylation of BAD (Bcl-2 antagonist of cell death BAD), a key mediator of the apoptotic pathway that plays a significant role in carcinogenesis and chemo-response [70,71], as well as GSK3β, which inhibits apoptosis, is highly expressed in breast cancer tissues, and has been associated with poor survival outcomes [72,73,74].